(WGLS use only):							Investigation(s):
W							
DNA loc							•

Initials

Wessex Genomics Laboratory Service (Salisbury) Salisbury District Hospital, Salisbury, Wilts. SP2 8BJ

Tel.: +44(0)1722 429080

E-mail: shc-tr.WRGLdutyscientist@nhs.net

Web: www.wrgl.org.uk




tralland South Genomics, Cen

Date of receipt:

In before?

Mainstream germline test for inherited cancer: Ovarian, Breast and Prostate

PATIENT DETAILS	Clinical details Please state in this box the full clinical details						
SURNAME	FORENAME	that meet the eligibility criteria overleaf: DNA will be stored and not tested unless these details are provided.					
Date of birth	NHS number						
Sex	Hospital number / Genetics number						
Consultant	Hospital / Department						
	NHS						
Additional copies to	Private (address for invoicing):						
Patient post code	GP name GP address						
		EDTA blood only					
Address to email final report: Please use an NHS digital accredited secure e-mail address	Date of collection						
The control of the co	, generio departironi e mai addresses die procinca	Collected by					
Please pick one of the following tests (tick in the appropriate box):							
R207 Inherited ovarian cancer (without breast cancer). R207 genes tested: BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, PALB2, and truncating variants in RAD51C and RAD51D. See overleaf for testing criteria.							
R208 Inherited breast cancer and	d ovarian cancer. R208 genes tested: <i>BRCA1</i> , d <i>RAD51D</i> . See overleaf for testing criteria.	· ·					
R430 Inherited prostate cancer. R430 genes tested: <i>BRCA1</i> , <i>BRCA2</i> , <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>PALB2</i> , and truncating varian <i>ATM</i> and <i>CHEK2</i> . See overleaf for testing criteria.							
R444 Breast cancer and metastatic, castration-resistant prostate cancer patients not meeting the R208/R430 criteria AND eligible for NICE approved PARP inhibitor treatment. R444 genes tested: <i>BRCA1 and BRCA2</i> . Note that M218.2 somatic tumour testing in prostate cancer should be performed as the first-line test, where possible.							
Referrals will only be accepted from one of the following: Consultant Clinical Geneticist / Registered Genetics Counsellor							
Consultant Clinical Geneticist / Registered Genetics Counsellor OR Consultant Oncologist (breast/gynaeoncology/urology)							
Consultant Surgeon (breast/gynaeoncology/urology)							
Breast Physician Clinical Nurse Specialist (breast/gynaeoncology/urology)							
Name of clinician consenting the patient:							
Please see next page for NHS England testing criteria. If the patient does not fulfil the testing criteria, the case should be discussed with Clinical Genetics (see link below).							
https://www.uhs.nhs.uk/ourservices/genetics/genetics.aspx							
In submitting this sample the clinician confirms that consent has been obtained for testing and storage.							



R208 - Relevant testing criteria for clinical indication R208: Inherited breast cancer and ovarian cancer

- 1. Living affected individual (proband) with breast (including high grade DCIS) or high grade ovarian cancer where the individual (with or without family history) meets at least one of the criteria. The proband has:
- a. Breast cancer (age < 40 years); OR
- b. Bilateral breast cancer (age < 60 years); OR
- c. Triple-negative breast cancer (age < 60 years); OR
- d. Assigned male at birth and affected with breast cancer (any age); OR
- e. Breast cancer (age <45 years) and a first-degree relative with breast cancer (age <45 years); OR
- f. Combined pathology-